Detalhe da pesquisa
1.
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Br J Haematol
; 204(5): 1762-1770, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500476
2.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31568564
3.
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Blood
; 132(3): 293-306, 2018 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695516
4.
Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Curr Oncol Rep
; 22(1): 6, 2020 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31981025
5.
Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.
Blood
; 130(20): 2180-2185, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28814386
6.
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
Br J Haematol
; 180(2): 267-270, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29143301
7.
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Oncology (Williston Park)
; 30(10): 914-20, 2016 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27753058
8.
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Br J Haematol
; 171(4): 530-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26343802
9.
CART19 in Hodgkin lymphoma: are we driving the right model?
Blood
; 132(10): 982-983, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190350
10.
Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Clin Adv Hematol Oncol
; 13(8): 518-24, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26351815
11.
KLRG1, Another Opportunity for a Breakthrough in MTCL.
Clin Cancer Res
; 30(11): 2300-2302, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568191
12.
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Oncoimmunology
; 13(1): 2351255, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38737792
13.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Clin Lymphoma Myeloma Leuk
; 24(4): 240-253, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195322
14.
On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?
Clin Cancer Res
; 29(20): 4024-4026, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581573
15.
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
Blood Adv
; 7(8): 1488-1495, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36287231
16.
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma.
Blood Adv
; 5(5): 1194-1198, 2021 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33635332
17.
Mantle cell lymphoma in relapse: the role of emerging new drugs.
Curr Opin Oncol
; 22(5): 419-23, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20679769
18.
Immunotherapy with drugs.
Hematology Am Soc Hematol Educ Program
; 2020(1): 598-605, 2020 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275686
19.
Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Curr Hematol Malig Rep
; 15(2): 125-129, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172360
20.
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Lancet Haematol
; 7(11): e808-e815, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010817